 |
If you or someone you know has recently been diagnosed with non-Hodgkin's
lymphoma (NHL), or are living with the disease, Zevalin® is available as a treatment option.
Zevalin is a form of cancer therapy called radioimmunotherapy, and is indicated for the
treatment of patients with relapsed or refractory, low-grade or follicular
B-cell non-Hodgkin's lymphoma, including patients with rituximab-refractory NHL. It was
approved by the Food and Drug Administration (FDA) in February of 2002 as the first
radioimmunotherapy agent for the treatment of NHL.
|
